[
    [
        {
            "time": "",
            "original_text": "乐普医疗：药物涂层冠脉球囊导管、左心耳封堵器系统获注册批准",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "药物涂层冠脉球囊导管",
                    "左心耳封堵器系统",
                    "注册批准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗器械",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "乐普医疗：药物涂层冠脉球囊导管、左心耳封堵器系统获注册批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "乐普医疗(300003.SZ)：药物涂层冠脉球囊导管获得NMPA注册批准",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "300003.SZ",
                    "药物涂层冠脉球囊导管",
                    "NMPA注册批准"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "乐普医疗(300003.SZ)：药物涂层冠脉球囊导管获得NMPA注册批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "乐普医疗(300003)：疫情影响逐渐消除，Q2扣非业绩超预期【2020年中报业绩预告点评|西南医药杜向阳团队】",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "300003",
                    "疫情影响",
                    "Q2扣非业绩",
                    "超预期",
                    "2020年中报业绩预告",
                    "西南医药杜向阳团队"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "乐普医疗(300003)：疫情影响逐渐消除，Q2扣非业绩超预期【2020年中报业绩预告点评|西南医药杜向阳团队】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]